Arijita Deb

660 total citations
34 papers, 445 citations indexed

About

Arijita Deb is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Arijita Deb has authored 34 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 7 papers in Epidemiology. Recurrent topics in Arijita Deb's work include Asthma and respiratory diseases (9 papers), Respiratory viral infections research (6 papers) and Pneumonia and Respiratory Infections (6 papers). Arijita Deb is often cited by papers focused on Asthma and respiratory diseases (9 papers), Respiratory viral infections research (6 papers) and Pneumonia and Respiratory Infections (6 papers). Arijita Deb collaborates with scholars based in United States, Canada and United Kingdom. Arijita Deb's co-authors include Usha Sambamoorthi, J. Douglas Thornton, Kim E. Innes, Xi Tan, Song Gao, Ming Hu, Sumit Basu, Zhen Yang, Bernard G. Schreurs and Kelly Johnson and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, BMC Infectious Diseases and Epidemiology and Infection.

In The Last Decade

Arijita Deb

28 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arijita Deb United States 9 116 107 89 74 60 34 445
Shih‐Tsung Huang Taiwan 14 37 0.3× 104 1.0× 119 1.3× 105 1.4× 148 2.5× 35 531
Željko Metelko Croatia 15 86 0.7× 209 2.0× 33 0.4× 39 0.5× 60 1.0× 80 830
Grant Maclaine United Kingdom 12 92 0.8× 99 0.9× 157 1.8× 138 1.9× 78 1.3× 23 505
Matthew Dahl Canada 14 55 0.5× 103 1.0× 75 0.8× 35 0.5× 88 1.5× 26 649
Juan del Llano Spain 9 68 0.6× 40 0.4× 66 0.7× 63 0.9× 146 2.4× 15 471
Mike Stedman United Kingdom 14 96 0.8× 94 0.9× 35 0.4× 104 1.4× 39 0.7× 71 734
Ashwin Kamath India 13 59 0.5× 44 0.4× 33 0.4× 32 0.4× 33 0.6× 65 600
Jens‐Ulrik Rosholm Denmark 11 60 0.5× 79 0.7× 44 0.5× 37 0.5× 22 0.4× 17 349
Donald O. Fedder United States 10 167 1.4× 128 1.2× 182 2.0× 138 1.9× 88 1.5× 26 1.2k
Javier Marta-Moreno Spain 5 67 0.6× 140 1.3× 91 1.0× 56 0.8× 17 0.3× 16 360

Countries citing papers authored by Arijita Deb

Since Specialization
Citations

This map shows the geographic impact of Arijita Deb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arijita Deb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arijita Deb more than expected).

Fields of papers citing papers by Arijita Deb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arijita Deb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arijita Deb. The network helps show where Arijita Deb may publish in the future.

Co-authorship network of co-authors of Arijita Deb

This figure shows the co-authorship network connecting the top 25 collaborators of Arijita Deb. A scholar is included among the top collaborators of Arijita Deb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arijita Deb. Arijita Deb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pongdee, Thanai, et al.. (2025). Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients with EGPA. Journal of Allergy and Clinical Immunology. 155(2). AB455–AB455.
2.
3.
Wang, Jiaxuan, Peter A. Howarth, Jeremiah Hwee, et al.. (2025). Low Adherence to Current Biologic Therapies in Asthma: Insights From a Retrospective Cohort Analysis of Claims Data. Journal of Allergy and Clinical Immunology. 155(2). AB439–AB439. 2 indexed citations
4.
Wechsler, Michael E., Anna Kovalszki, Jared Silver, et al.. (2025). Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice. Journal of Allergy and Clinical Immunology Global. 4(2). 100437–100437.
5.
6.
Mathur, Sameer K., et al.. (2024). Eosinophil count testing in patients with asthma varies by healthcare provider type in the US: a retrospective study. Allergy Asthma and Clinical Immunology. 20(1). 56–56.
7.
Mathur, Sameer K., et al.. (2024). Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States. Annals of Allergy Asthma & Immunology. 134(3). 341–350.e2. 2 indexed citations
8.
Casale, Thomas B., Thomas Corbridge, Guillaume Germain, et al.. (2024). Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma. Allergy Asthma and Clinical Immunology. 20(1). 25–25. 1 indexed citations
9.
Bernstein, Jonathan A., Jared Silver, Elizabeth Packnett, et al.. (2024). Real-world unified airway benefits of mepolizumab. Annals of Allergy Asthma & Immunology. 133(4). 422–429.e2. 1 indexed citations
10.
Han, Joseph K., et al.. (2024). Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps. Annals of Allergy Asthma & Immunology. 134(6). 685–693.e5. 5 indexed citations
11.
Silver, Jared, Elizabeth Packnett, Julie Park, & Arijita Deb. (2023). Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study. Allergy Asthma and Clinical Immunology. 19(1). 104–104. 3 indexed citations
12.
Silver, Jared, et al.. (2023). Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. International Forum of Allergy & Rhinology. 14(1). 5–17. 4 indexed citations
13.
Deb, Arijita, et al.. (2022). Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany. BMC Infectious Diseases. 22(1). 753–753. 4 indexed citations
14.
Owusu‐Edusei, Kwame, Arijita Deb, & Kelly Johnson. (2022). Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA. Infectious Diseases and Therapy. 11(3). 987–999. 8 indexed citations
15.
Paganino, Chiara, Daniela Amicizia, Cecilia Trucchi, et al.. (2021). Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy. Vaccines. 9(12). 1380–1380. 6 indexed citations
16.
Deb, Arijita, et al.. (2018). Tumor Necrosis Factor Inhibitor Therapy and The Risk of Developing Depression Among Working-Age Adults with Rheumatoid Arthritis. Value in Health. 21(1). S192–S192. 8 indexed citations
17.
Deb, Arijita, Usha Sambamoorthi, J. Douglas Thornton, Bernard G. Schreurs, & Kim E. Innes. (2017). Direct medical expenditures associated with Alzheimer's and related dementias (ADRD) in a nationally representative sample of older adults – an excess cost approach. Aging & Mental Health. 22(5). 619–624. 49 indexed citations
18.
19.
Sambamoorthi, Usha, Xi Tan, & Arijita Deb. (2015). Multiple chronic conditions and healthcare costs among adults. Expert Review of Pharmacoeconomics & Outcomes Research. 15(5). 823–832. 86 indexed citations
20.
Gao, Song, Sumit Basu, Zhen Yang, Arijita Deb, & Ming Hu. (2012). Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents. Current Drug Targets. 13(14). 1885–1899. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shih‐Tsung Huang Breakdown of academic impact, for papers by Željko Metelko Breakdown of academic impact, for papers by Grant Maclaine Breakdown of academic impact, for papers by Matthew Dahl Breakdown of academic impact, for papers by Juan del Llano Breakdown of academic impact, for papers by Mike Stedman Breakdown of academic impact, for papers by Ashwin Kamath Breakdown of academic impact, for papers by Jens‐Ulrik Rosholm Breakdown of academic impact, for papers by Donald O. Fedder Breakdown of academic impact, for papers by Javier Marta-Moreno
Rankless by CCL
2026